沙芬酰胺治疗帕金森病的研究进展

Research progress of safinamide in treatment of Parkinson's diseases

帕金森病(Parkinson’s disease,PD)是仅次于阿尔茨海默病的第2大神经退行性疾病。目前,有效治疗PD的主要途径是服用左旋多巴,但是,长时间服用左旋多巴会导致一系列副作用,如运动障碍、恶心、失眠、疗效减退、"开关"现象等。沙芬酰胺于2017年3月21被美国FDA批准用于治疗PD,作为治疗PD的新型药物,具有选择性高、安全性好等优点。该文介绍了可逆单胺氧化酶抑制剂——沙芬酰胺治疗PD的作用机制及近几年的部分临床研究进展。

Parkinson's disease(PD)is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer's disease.Over the decades,levodopa has been considered the main therapy against PD.However,long term use of levodopa is often accompanied by adverse reactions,including nausea,insomnia,dyskinesia,and"wearing-off"and"on-off"phenomena,ranging in severity from mild and non-disabling to incapacitating.On March212017,US Food and Drug Administration(FDA)approved safinamide as an adjunctive treatment to levodopa in patients with PD experiencing"off"episodes.As a new drug for the treatment of PD,safinamide has the advantage of high selectivity and safety.This paper reviews the mechanisms and some clinical trials of safinamide.